Trevi Therapeutics (TRVI) Preferred Shares (2018)

Trevi Therapeutics' (TRVI) quarterly Preferred Shares came in at $33.7 million in Q4 2018.

Trevi Therapeutics (TRVI) Preferred Shares (2018) Analysis & Trends

Trevi Therapeutics' Preferred Shares history runs 1 years deep, the most recent figure standing at $33.7 million for Q4 2018.

On a quarterly basis, Preferred Shares changed N/A year-over-year to $33.7 million in Q4 2018; TTM through Dec 2018 was $33.7 million, a N/A change from a year earlier, with the FY2018 full-year figure at $33.7 million, changed N/A from the prior year.
Preferred Shares steadied at $33.7 million in Q4 2018 per TRVI's latest filing.
Across five years, Preferred Shares topped out at $33.7 million in Q4 2018 and bottomed at $33.7 million in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Trevi Therapeutics	2.50 Bn	2.50 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	33.70 Mn